---

Ross C. Terrell I n 1961, Terrell took up the challenge to create a new anesthetic that would be free of any of the problems associated with inhalation agents then in uses, all of which had at least one serious disadvantage: odor, flammability, slow recovery, cardiac arrhythmias, or narrow margin of safety. He pioneered the drug discovery effort, both the synthesis and methodology to identify novel inhalation anesthetics. Terrell's research resulted in the discovery of enflurane (Ethrane) and isoflurane (Forane), both of which are marketed compounds. Another important compound, desflurane (Suprane) is in phase III clinical trials. Enflurane has been used in more than 100 million surgeries and isoflurane in more than 120 million surgical patients worldwide. In the U.S., isoflurane is used in 8 of 10 surgical procedures requiring an inhalation anesthetic. Terrell has 60 patents when he retired from Anaquest in 1987. He continues to serve Anaquest as a consultant when not engaged in his new avocation - part-time chef in a New York restaurant.